BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol 2015; 21(41): 11597-11608 [PMID: 26556989 DOI: 10.3748/wjg.v21.i41.11597] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 16.8] [Reference Citation Analysis]
2 Tedesco D, Thapa M, Chin CY, Ge Y, Gong M, Li J, Gumber S, Speck P, Elrod EJ, Burd EM, Kitchens WH, Magliocca JF, Adams AB, Weiss DS, Mohamadzadeh M, Grakoui A. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease. Gastroenterology 2018;154:2178-93. [PMID: 29454797 DOI: 10.1053/j.gastro.2018.02.019] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 16.0] [Reference Citation Analysis]
3 Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
4 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 15.5] [Reference Citation Analysis]
5 Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol 2018;31:296-304. [PMID: 29720855 DOI: 10.20524/aog.2018.0248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Liu B, Zeng Q, Chen H, Liao J, Bai Y, Han Q, Qiao N, Wang S, Mehmood K, Hussain R, Ahmed BZ, Tang Z, Zhang H, Li Y. The hepatotoxicity of altrazine exposure in mice involves the intestinal microbiota. Chemosphere 2021;272:129572. [PMID: 33485040 DOI: 10.1016/j.chemosphere.2021.129572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
7 Lu H, Chen L, Pan X, Yao Y, Zhang H, Zhu X, Lou X, Zhu C, Wang J, Li L, Wu Z. Lactitol Supplementation Modulates Intestinal Microbiome in Liver Cirrhotic Patients. Front Med (Lausanne) 2021;8:762930. [PMID: 34722597 DOI: 10.3389/fmed.2021.762930] [Reference Citation Analysis]
8 Dai J, Yang X, Yuan Y, Jia Y, Liu G, Lin N, Xiao H, Zhang L, Chen J. Toxicity, gut microbiota and metabolome effects after copper exposure during early life in SD rats. Toxicology 2020;433-434:152395. [PMID: 32027963 DOI: 10.1016/j.tox.2020.152395] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
9 Zheng R, Wang G, Pang Z, Ran N, Gu Y, Guan X, Yuan Y, Zuo X, Pan H, Zheng J, Wang F. Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma. Cancer Med 2020;9:4232-50. [PMID: 32281295 DOI: 10.1002/cam4.3045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
10 Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, Alessandria C. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World J Hepatol 2019; 11(6): 489-512 [PMID: 31293718 DOI: 10.4254/wjh.v11.i6.489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
11 Fukawa A, Baba S, Iwasawa K, Yamaguchi M, Hosono A. Dietary α-Lactalbumin protects against thioacetamide-induced liver cirrhosis by maintaining gut-liver axis function in rats. Bioscience, Biotechnology, and Biochemistry 2020;84:171-7. [DOI: 10.1080/09168451.2019.1660613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Salgüero S, Rojo D, Berenguer J, González-García J, Fernández-Rodríguez A, Brochado-Kith O, Díez C, Hontañon V, Virseda-Berdices A, Martínez J, Ibañez-Samaniego L, Llop-Herrera E, Barbas C, Resino S, Jiménez-Sousa MA; Escorial Study Group. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients. Liver Int 2020;40:2215-27. [PMID: 32593189 DOI: 10.1111/liv.14580] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chen Y, Liu P, Liu R, Hu S, He Z, Dong G, Feng C, An S, Ying X. Comprehensive Strain-Level Analysis of the Gut Microbe Faecalibacterium prausnitzii in Patients with Liver Cirrhosis. mSystems 2021;6:e0077521. [PMID: 34342541 DOI: 10.1128/mSystems.00775-21] [Reference Citation Analysis]
14 Liu J, Xu Y, Jiang B. Novel Insights Into Pathogenesis and Therapeutic Strategies of Hepatic Encephalopathy, From the Gut Microbiota Perspective. Front Cell Infect Microbiol 2021;11:586427. [PMID: 33692964 DOI: 10.3389/fcimb.2021.586427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Shi Y, Leng Y, Liu D, Liu X, Ren Y, Zhang J, Chen F. Research Advances in Protective Effects of Ursolic Acid and Oleanolic Acid Against Gastrointestinal Diseases. Am J Chin Med 2021;49:413-35. [PMID: 33622215 DOI: 10.1142/S0192415X21500191] [Reference Citation Analysis]
16 Sagi H, Shibuya S, Kato T, Nakanishi Y, Tsuboi A, Moriya S, Ohno H, Miyamoto H, Kodama H, Shimizu T. SOD1 deficiency alters gastrointestinal microbiota and metabolites in mice. Exp Gerontol 2020;130:110795. [PMID: 31805337 DOI: 10.1016/j.exger.2019.110795] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Chen M, Zheng J, Zou X, Ye C, Xia H, Yang M, Gao Q, Yang Q, Liu H. Ligustrum robustum (Roxb.) blume extract modulates gut microbiota and prevents metabolic syndrome in high-fat diet-fed mice. J Ethnopharmacol 2021;268:113695. [PMID: 33316365 DOI: 10.1016/j.jep.2020.113695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Shao M, Zhu Y. Long-term metal exposure changes gut microbiota of residents surrounding a mining and smelting area. Sci Rep 2020;10:4453. [PMID: 32157109 DOI: 10.1038/s41598-020-61143-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
19 Malikowski T, Khanna S, Pardi DS. Fecal microbiota transplantation for gastrointestinal disorders. Curr Opin Gastroenterol 2017;33:8-13. [PMID: 28134687 DOI: 10.1097/MOG.0000000000000326] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
20 Chen J, Deng X, Liu Y, Tan Q, Huang G, Che Q, Guo J, Su Z. Kupffer Cells in Non-alcoholic Fatty Liver Disease: Friend or Foe? Int J Biol Sci 2020;16:2367-78. [PMID: 32760204 DOI: 10.7150/ijbs.47143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
21 Zhang H, Yan A, Liu X, Ma Y, Zhao F, Wang M, Loor JJ, Wang H. Melatonin ameliorates ochratoxin A induced liver inflammation, oxidative stress and mitophagy in mice involving in intestinal microbiota and restoring the intestinal barrier function. Journal of Hazardous Materials 2021;407:124489. [DOI: 10.1016/j.jhazmat.2020.124489] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
22 Wei X, Jiang S, Chen Y, Zhao X, Li H, Lin W, Li B, Wang X, Yuan J, Sun Y. Cirrhosis related functionality characteristic of the fecal microbiota as revealed by a metaproteomic approach. BMC Gastroenterol 2016;16:121. [PMID: 27716148 DOI: 10.1186/s12876-016-0534-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
23 Zha H, Chen Y, Wu J, Chang K, Lu Y, Zhang H, Xie J, Wang Q, Tang R, Li L. Characteristics of three microbial colonization states in the duodenum of the cirrhotic patients. Future Microbiol 2020;15:855-68. [PMID: 32662659 DOI: 10.2217/fmb-2019-0270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Bloom PP, Luévano JM Jr, Miller KJ, Chung RT. Deep stool microbiome analysis in cirrhosis reveals an association between short-chain fatty acids and hepatic encephalopathy. Ann Hepatol 2021;25:100333. [PMID: 33621653 DOI: 10.1016/j.aohep.2021.100333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ramirez M, Pell N, Mejias M, Fernandez M. Pericytes in the Gut. Adv Exp Med Biol 2019;1122:73-100. [PMID: 30937864 DOI: 10.1007/978-3-030-11093-2_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Neag MA, Catinean A, Muntean DM, Pop MR, Bocsan CI, Botan EC, Buzoianu AD. Probiotic Bacillus Spores Protect Against Acetaminophen Induced Acute Liver Injury in Rats. Nutrients 2020;12:E632. [PMID: 32120994 DOI: 10.3390/nu12030632] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
27 Porras D, Nistal E, Martínez-flórez S, Pisonero-vaquero S, Olcoz JL, Jover R, González-gallego J, García-mediavilla MV, Sánchez-campos S. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Free Radical Biology and Medicine 2017;102:188-202. [DOI: 10.1016/j.freeradbiomed.2016.11.037] [Cited by in Crossref: 184] [Cited by in F6Publishing: 176] [Article Influence: 46.0] [Reference Citation Analysis]
28 Roda A, Aldini R, Camborata C, Spinozzi S, Franco P, Cont M, D'Errico A, Vasuri F, Degiovanni A, Maroni L, Adorini L. Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis. Clin Transl Sci 2017;10:292-301. [PMID: 28411380 DOI: 10.1111/cts.12468] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
29 Voiosu A, Wiese S, Voiosu T, Bendtsen F, Møller S. Bile acids and cardiovascular function in cirrhosis. Liver Int 2017;37:1420-30. [DOI: 10.1111/liv.13394] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
30 Liu X, Sun R, Li Z, Xiao R, Lv P, Sun X, Olson MA, Gong Y. Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis. Arch Biochem Biophys 2021;711:109019. [PMID: 34478730 DOI: 10.1016/j.abb.2021.109019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Shao Y, Jiang Y, Li H, Zhang F, Hu Z, Zheng S. Characteristics of mouse intestinal microbiota during acute liver injury and repair following 50% partial hepatectomy. Exp Ther Med 2021;22:953. [PMID: 34335895 DOI: 10.3892/etm.2021.10385] [Reference Citation Analysis]
32 Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373-1388. [PMID: 29485654 DOI: 10.1039/c7fo01528c] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 8.3] [Reference Citation Analysis]
33 Bellar A, Welch N, Dasarathy S. Exercise and physical activity in cirrhosis: opportunities or perils. J Appl Physiol (1985) 2020;128:1547-67. [PMID: 32240017 DOI: 10.1152/japplphysiol.00798.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Tajiri K, Shimizu Y. Gut bacteria may control development of hepatocellular carcinoma. Hepatobiliary Surg Nutr 2017;6:417-9. [PMID: 29312980 DOI: 10.21037/hbsn.2017.07.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol 2018;15:467-79. [PMID: 29413959 DOI: 10.1016/j.redox.2018.01.009] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 27.0] [Reference Citation Analysis]
36 Chen MX, Wang SY, Kuo CH, Tsai IL. Metabolome analysis for investigating host-gut microbiota interactions. J Formos Med Assoc. 2019;118 Suppl 1:S10-S22. [PMID: 30269936 DOI: 10.1016/j.jfma.2018.09.007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 12.7] [Reference Citation Analysis]
37 Philips CA, Augustine P, Yerol PK, Ramesh GN, Ahamed R, Rajesh S, George T, Kumbar S. Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease. J Clin Transl Hepatol. 2020;8:87-99. [PMID: 32274349 DOI: 10.14218/jcth.2019.00035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
38 Zhang Y, Zhao M, Jiang X, Qiao Q, Liu T, Zhao C, Wang M. Comprehensive Analysis of Fecal Microbiome and Metabolomics in Hepatic Fibrosis Rats Reveal Hepatoprotective Effects of Yinchen Wuling Powder From the Host-Microbial Metabolic Axis. Front Pharmacol 2021;12:713197. [PMID: 34385924 DOI: 10.3389/fphar.2021.713197] [Reference Citation Analysis]
39 Kourkoumpetis T, Sood G. Pathogenesis of Alcoholic Liver Disease: An Update. Clin Liver Dis 2019;23:71-80. [PMID: 30454834 DOI: 10.1016/j.cld.2018.09.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
40 Zhao W, Xiao M, Yang J, Zhang L, Ba Y, Xu R, Liu Z, Zou H, Yu P, Wu X, Chen X. The combination of Ilexhainanoside D and ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease. Phytomedicine 2019;63:153039. [DOI: 10.1016/j.phymed.2019.153039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
41 Neag MA, Mitre AO, Catinean A, Buzoianu AD. Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. World J Gastroenterol 2021; 27(43): 7446-7461 [DOI: 10.3748/wjg.v27.i43.7446] [Reference Citation Analysis]
42 Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017;9. [PMID: 29035308 DOI: 10.3390/nu9101124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 20.0] [Reference Citation Analysis]
43 Himoto T, Masaki T. Current Trends of Essential Trace Elements in Patients with Chronic Liver Diseases. Nutrients 2020;12:E2084. [PMID: 32674425 DOI: 10.3390/nu12072084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
44 Li C, Zhang B, Wang X, Pi X, Wang X, Zhou H, Mai K, He G. Improved utilization of soybean meal through fermentation with commensal Shewanella sp. MR-7 in turbot (Scophthalmus maximus L.). Microb Cell Fact 2019;18:214. [PMID: 31842889 DOI: 10.1186/s12934-019-1265-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
45 Stadlbauer V, Komarova I, Klymiuk I, Durdevic M, Reisinger A, Blesl A, Rainer F, Horvath A. Disease severity and proton pump inhibitor use impact strongest on faecal microbiome composition in liver cirrhosis. Liver Int 2020;40:866-77. [PMID: 31943691 DOI: 10.1111/liv.14382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
46 Ahlawat S, Asha, Sharma KK. Gut-organ axis: a microbial outreach and networking. Lett Appl Microbiol 2021;72:636-68. [PMID: 32472555 DOI: 10.1111/lam.13333] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
47 Altamirano-barrera A, Uribe M, Chávez-tapia NC, Nuño-lámbarri N. The role of the gut microbiota in the pathology and prevention of liver disease. The Journal of Nutritional Biochemistry 2018;60:1-8. [DOI: 10.1016/j.jnutbio.2018.03.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
48 Feder S, Wiest R, Weiss TS, Aslanidis C, Schacherer D, Krautbauer S, Liebisch G, Buechler C. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis. Lipids Health Dis 2021;20:6. [PMID: 33461570 DOI: 10.1186/s12944-021-01431-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
49 Fu ZD, Cui JY. Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. Curr Pharmacol Rep 2017;3:101-13. [PMID: 28983453 DOI: 10.1007/s40495-017-0087-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
50 Malnick SDH, Fisher D, Somin M, Neuman MG. Treating the Metabolic Syndrome by Fecal Transplantation-Current Status. Biology (Basel) 2021;10:447. [PMID: 34065241 DOI: 10.3390/biology10050447] [Reference Citation Analysis]
51 Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mitoro A, Yamao J, Yoshiji H. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. Hepatol Res 2019;49:232-8. [PMID: 30198141 DOI: 10.1111/hepr.13249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]